5-O-ethyl 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-O-ethyl 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
• 化学式: C39H46N4O13
• 分子量: 778.8
• InChiKey: NCROCUGFEFQXTA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.54
• 重原子数：
  56
• 可旋转键数：
  15
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  230
• 氢给体数：
  2
• 氢受体数：
  15

文献信息

• [EN] A NOVEL THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA (EPP) AND X-LINKED PROTOPORPHYRIA (XLP)<br/>[FR] NOUVELLE THÉRAPIE POUR LA PROTOPORPHYRIE ÉRYTHROPOÏÉTIQUE (EPP) ET LA PROTOPORPHYRIE LIÉE AU CHROMOSOME X (XLP)
  申请人：UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION

  公开号：WO2020236901A1

  公开（公告）日：2020-11-26

  Disclosed are novel compositions and methods of using the same for the treatment of Erythropoiefic protoporphyria (EPP) and X-linked protoporphyria (XLP). Disclosed are methods and compositions related to treating Erythropoietic protoporphyria and X-linked protoporphyria. Also described are therapeutic agents that can inhibit ABCG2. For example, provided herein are therapeutic agents defined by Formula I.

  揭示了用于治疗红细胞生成前卟啉病（EPP）和X连锁前卟啉病（XLP）的新型组合物和使用方法。揭示了与治疗红细胞生成前卟啉病和X连锁前卟啉病相关的方法和组合物。还描述了可以抑制ABCG2的治疗剂。例如，本文提供了由式I定义的治疗剂。
• A NOVEL THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA (EPP) AND X-LINKED PROTOPORPHYRIA (XLP)
  申请人：University of Pittsburgh - of the Commonwealth System of Higher Education

  公开号：EP3972605A1

  公开（公告）日：2022-03-30